ENDP
Endo International plcENDP
ENDP
Delisted
ENDP was delisted on the 25th of August, 2022.
About: Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL. The majority of its revenue comes from the United States.
Employees: 3,103
Financial journalist opinion
Neutral
Investopedia
2 months ago
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange (NYSE), the two drugmakers said Thursday.
Positive
Reuters
1 year ago
Drugmaker Endo receives US court approval for bankruptcy restructuring
Bankrupt drugmaker Endo International said on Tuesday a U.S. Bankruptcy Court has approved its restructuring plan and related opioid settlements to emerge from bankruptcy, which began in 2022.
Negative
Reuters
1 year ago
Drugmaker Endo reaches $465 mln bankruptcy settlement with US government
The U.S. Department of Justice said Thursday that it has reached a $465 million settlement with bankruptcy drugmaker Endo International, resolving the federal government's law enforcement, tax, and health care cost claims.
Charts implemented using Lightweight Charts™